Q2 2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Hengrui Pharma(600276) the Revenue is 7.315 B (-14.5%), Miss estimate;the EBIT is 2.48 B (-19.29%), Miss estimate;the EPS is 0.34 (-15%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
7.32B14.50%
8.87B3.62%
-1.55B18.12%
EBITMiss expectations
2.48B19.29%
2.52B17.94%
-0.04B1.35%
EPSMiss expectations
0.3415.00%
0.3980.50%
-0.058014.50%
Revenue
ActualEstimateUnit: CNY
qf
EBIT
ActualEstimateUnit: CNY
qf
Net income
ActualEstimateUnit: CNY
qf
EPS
ActualEstimateUnit: CNY
qf